¶ Helicobacter pylori
¶ Definition
Helicobacter pylori is a spiral-shaped, flagellated Gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of humans worldwide, exhibiting phylogeographic patterns that mirror human migration dating back 58,000 years. Once considered solely a pathogen responsible for peptic ulcers and gastric cancer, H. pylori is now recognized as an ancient human commensal whose presence or absence represents a critical evolutionary trade-off with profound immunometabolic consequences.
¶ Picture It
Imagine H. pylori as a specialized Arctic explorer living in one of Earth's most hostile environments—the acidic stomach, with pH 1.5-3.5. This explorer carries its own portable alkaline shield generator (urease enzyme) that converts urea into ammonia, creating a protective microenvironment bubble just alkaline enough to survive. Using corkscrew-shaped propellers (flagella), it drills through the stomach's protective mucus layer and stakes tent pegs (adhesins) into the epithelial cell surface. Once established, it sends out diplomatic signals that train the local immune garrison, teaching it moderation and preventing overreaction to food antigens. However, like a long-term resident who knows too much about the neighborhood, its virulence factors (CagA, VacA) can occasionally trigger inflammatory neighborhood watch meetings that spiral into chronic gastritis. The paradox: evict this ancient resident, and the lower esophagus—previously protected by gastric acid regulation—becomes vulnerable to acid reflux and cancer. Keep the resident too long with the wrong strain, and the stomach itself may develop ulcers or malignancy. It's a 58,000-year-old roommate agreement with complex terms.
¶ Mechanism
H. pylori's gastric colonization and immune modulation occur through multiple coordinated mechanisms:
Acid Survival and Motility:
- Urease enzyme (UreA/UreB) converts urea → ammonia (NH₃) + CO₂
- NH₃ raises local pH from ~2.0 to 6.0-7.0, creating microenvironment allowing bacterial survival
- Flagella (FlaA/FlaB) enable corkscrew motility through viscous mucus layer (200-450 μm thick)
- Chemotaxis receptors (TlpA-D) guide bacteria toward epithelial surface
Epithelial Adhesion:
- BabA adhesin binds Lewis-b (Leb) blood group antigens on gastric epithelial cells
- SabA adhesin binds sialyl-Lewis-x antigens
- OipA (outer inflammatory protein) enhances IL-8 secretion
- Adherence triggers pedestal formation in epithelial cells
Virulence Factor Delivery:
- Type IV secretion system (T4SS) encoded by cag pathogenicity island (cagPAI)
- CagA protein translocated into host epithelial cells → phosphorylated by Src/Abl kinases
- Phosphorylated CagA activates SHP2 phosphatase → ERK1/2 MAPK → cellular proliferation
- CagA disrupts tight junctions (ZO-1, occludin) → increased permeability
- VacA toxin forms membrane pores → cellular vacuolation, cytochrome c release → apoptosis
- VacA impairs T-cell activation and proliferation
Immune Response Cascade:
- Epithelial cells detect H. pylori via TLR4/TLR2 → NF-κB activation
- NF-κB → IL-8, IL-1β, TNF-α secretion
- IL-8 recruits neutrophils to gastric mucosa (chronic gastritis hallmark)
- Dendritic cells present H. pylori antigens → Th1/Th17 response
- Chronic infection → Treg induction (immunomodulation)
- ROS production by neutrophils → DNA damage → gastric atrophy over decades
Acid Regulation Effects:
- H. pylori colonization → reduced somatostatin from D cells
- Lower somatostatin → increased gastrin from G cells
- Hypergastrinemia → increased acid secretion initially (duodenal ulcer phenotype)
- Chronic inflammation → parietal cell loss → hypochlorhydria (gastric cancer phenotype)
graph TD
A[H. pylori colonization] --> B["Urease: Urea → NH₃"]
B --> C[Local pH 6-7 microenvironment]
A --> D[CagA via T4SS]
D --> E[CagA phosphorylation by Src/Abl]
E --> F["SHP2 → ERK1/2 → Proliferation"]
A --> G[VacA toxin]
G --> H[Membrane pore formation]
H --> I["Vacuolation + Apoptosis"]
A --> J[TLR4/TLR2 activation]
J --> K["NF-κB → IL-8, TNF-α"]
K --> L[Neutrophil infiltration]
L --> M[Chronic gastritis]
M --> N{Outcome depends on strain + host}
N --> O["Duodenal ulcer: High acid"]
N --> P["Gastric atrophy: Low acid"]
N --> Q["Gastric cancer: Intestinal metaplasia"]
A --> R["↓Somatostatin → ↑Gastrin"]
R --> O
Protective Mechanisms (Absence-Related Pathology):
- H. pylori presence → Treg expansion → systemic immune tolerance
- Ghrelin regulation by H. pylori → appetite and metabolic signaling
- Acid suppression prevents esophageal acid reflux
- Loss of H. pylori → loss of immunoregulatory signals → increased GERD, esophageal adenocarcinoma risk (OR 1.8-2.4)
¶ Clinical Significance
H. pylori represents a paradigmatic example of evolutionary mismatch and antagonistic pleiotropy in cPNI. Its clinical significance must be evaluated through a dual lens:
Traditional Pathogenic Role:
- Most common cause of peptic ulcers (70% of gastric ulcers, 90% of duodenal ulcers)
- Multivariable hazard ratio for gastric disease: 1.68
- WHO Class I carcinogen for gastric adenocarcinoma (chronic infection → 1-3% lifetime cancer risk)
- CagA-positive strains confer 2-3× higher cancer risk than CagA-negative strains
- Associated with gastric MALT lymphoma, atrophic gastritis, intestinal metaplasia
Evolutionary Commensal Role:
- Present in humans for >58,000 years—phylogeography matches human migration (African, European, Asian, Amerindian strains)
- Prevalence inversely correlates with asthma, allergies, IBD (hygiene hypothesis/old friends mechanism)
- Absence associated with increased GERD (OR 2.1), Barrett's esophagus, esophageal adenocarcinoma (OR 1.8-2.4)
- Early-life colonization may program immune tolerance via Treg induction
- H. pylori-positive individuals show lower allergic rhinitis and atopic dermatitis rates
cPNI Clinical Decision Framework:
The decision to eradicate H. pylori requires integration across multiple metamodels:
-
Metamodel 1 (Chronic Low-Grade Inflammation):
- H. pylori contributes to chronic gastritis, elevated IL-8, neutrophil activation
- However, its immune-training effects may prevent broader systemic inflammation
- Consider eradication in symptomatic gastritis, documented ulcers, or family history of gastric cancer
-
Metamodel 3 (Dysbiosis):
- H. pylori presence elevates gastric pH → permits overgrowth of oral pathogens (Porphyromonas gingivalis, Staphylococcus aureus) in stomach
- Elevated pH (>4) associated with gastric dysbiosis
- Post-eradication: PPI continuation worsens dysbiosis—minimize PPI duration
-
Evolutionary Medicine Perspective:
- Universal eradication protocols ignore evolutionary co-adaptation
- Strain typing matters: CagA-positive strains warrant eradication; CagA-negative may not
- Geographic ancestry affects strain virulence (East Asian CagA variants more oncogenic)
- Test-and-treat approach based on symptoms, strain, and cancer risk factors (family history, atrophic gastritis)
Standard Eradication Protocol:
- Triple therapy: PPI (omeprazole 20mg bid) + amoxicillin (1g bid) + clarithromycin (500mg bid) × 14 days
- Quadruple therapy (if resistance): PPI + bismuth + tetracycline + metronidazole × 14 days
- Eradication success: 85-90% with triple therapy (declining due to antibiotic resistance)
- Confirm eradication: Urea breath test or stool antigen test 4-6 weeks post-treatment
Clinical Thresholds:
- Pepsinogen I/II ratio
.0: atrophic gastritis (pre-cancerous) - Gastrin >100 pg/mL: hypergastrinemia (H. pylori-induced or PPI-induced)
- Calprotectin (gastric juice) >50 μg/g: active inflammation
- CagA IgG antibodies: marker of virulent strain exposure (persistent even after eradication)
Intervention Implications:
- Avoid routine eradication in asymptomatic young patients without cancer risk factors
- Prioritize eradication in: active ulcer disease, MALT lymphoma, post-gastric cancer resection, strong family history
- Address post-eradication dysbiosis: probiotics (Lactobacillus, Bifidobacterium), fermented foods, minimize PPI duration
- Consider micronutrient repletion post-eradication: vitamin B12, iron (chronic H. pylori impairs absorption)
¶ Key Facts
- H. pylori colonizes 50% of global population, with higher prevalence in developing countries (70-90%)
- Phylogeographic analysis identifies seven distinct populations mirroring human migration: hpAfrica1, hpAfrica2, hpNEAfrica, hpEurope, hpAsia2, hpEastAsia, hpAmerind
- Urease activity raises local gastric pH from 2.0 to 6.0-7.0, essential for bacterial survival
- CagA-positive strains increase gastric cancer risk 2-3× compared to CagA-negative strains
- VacA forms hexameric membrane pores, inducing vacuolation and apoptosis
- Multivariable hazard ratio for H. pylori infection in gastric disease: 1.68
- Absence of H. pylori increases GERD risk (OR 2.1) and esophageal adenocarcinoma risk (OR 1.8-2.4)
- Gastric pH elevation (>4) permits colonization by oral bacteria: Porphyromonas gingivalis, Staphylococcus aureus
- Standard triple therapy eradication rate: 85-90% (declining due to clarithromycin resistance reaching 15-40% in some regions)
- Early-life H. pylori acquisition associated with 30-50% lower asthma and allergy rates (protective immunomodulation)
- Chronic H. pylori infection reduces ghrelin levels, potentially affecting appetite and metabolic regulation
- Post-eradication, continued PPI use worsens gastric dysbiosis—minimize duration to 2-4 weeks
¶ Connections
- gastric ulcers — H. pylori is causative in 70% of gastric ulcers, 90% of duodenal ulcers via acid dysregulation and mucosal damage
- gastric mucosa — primary colonization site where H. pylori adheres to epithelial cells and induces chronic inflammation
- gastric cancer — chronic H. pylori infection (especially CagA+) increases adenocarcinoma risk 2-6× via atrophy-metaplasia-dysplasia cascade
- PPI — used in eradication protocols to reduce acid and enhance antibiotic efficacy; prolonged use post-eradication worsens dysbiosis
- antibiotics — triple or quadruple therapy required for eradication; rising resistance (clarithromycin 15-40%) threatens efficacy
- urease — key enzyme enabling H. pylori survival by converting urea → ammonia, raising local pH to 6.0-7.0
- ammonia — urease byproduct creating alkaline microenvironment; also cytotoxic at high concentrations
- pH regulation — H. pylori modulates gastric pH via urease and by suppressing somatostatin, increasing gastrin
- dysbiosis — H. pylori-induced pH elevation (>4) permits oral pathogen overgrowth in stomach
- Porphyromonas gingivalis — oral pathogen co-occurring with H. pylori in dysbiotic, alkaline stomach environment
- Staphylococcus aureus — co-colonizes dysbiotic stomach with elevated pH alongside H. pylori
- GERD — absence of H. pylori increases risk 2.1× by removing acid-suppressing immune signals
- esophageal cancer — adenocarcinoma risk increases 1.8-2.4× when H. pylori absent (loss of protective acid suppression)
- inflammation — chronic gastritis driven by IL-8, TNF-α, neutrophil infiltration in response to H. pylori
- neutrophils — primary inflammatory cells recruited via IL-8; chronic presence defines H. pylori gastritis
- cytokines — IL-8, IL-1β, TNF-α released by epithelial cells and immune cells in response to H. pylori TLR4 activation
- IL-8 — key neutrophil chemoattractant upregulated 10-50× by H. pylori CagA and VacA
- NF-κB — transcription factor activated by H. pylori TLR4 signaling, driving pro-inflammatory cytokine expression
- TLR4 — pattern recognition receptor detecting H. pylori LPS, initiating inflammatory cascade
- microbiome — H. pylori is dominant member of gastric microbiome, shaping ecosystem via pH and immune modulation
- gut barrier — H. pylori CagA disrupts tight junctions (ZO-1, occludin), increasing gastric permeability
- gastritis — chronic active gastritis with neutrophil and lymphocyte infiltration is hallmark of H. pylori infection
- Treg cells — expanded by chronic H. pylori infection, providing systemic immune tolerance and allergy protection
- evolution — H. pylori co-evolved with humans for 58,000+ years, phylogeography mirrors human migration patterns
- old friends mechanism — H. pylori represents ancient commensal whose loss contributes to rising allergic/autoimmune disease
- antagonistic pleiotropy — H. pylori's protective effects (immune tolerance, GERD prevention) trade off against cancer risk in aging
- molecular mimicry — H. pylori antigens cross-react with gastric H+/K+-ATPase, potentially triggering autoimmune gastritis
- chronic low-grade inflammation — H. pylori maintains persistent inflammatory state in stomach, contributing to Metamodel 1 pathology
- antibiotic resistance — rising clarithromycin resistance (15-40%) threatens eradication efficacy, requiring alternative regimens
- immune tolerance — H. pylori induces Treg expansion and tolerogenic dendritic cells, reducing allergic responses
- ghrelin — appetite hormone whose levels are reduced by H. pylori infection, affecting satiety and metabolism
- vitamin B12 — chronic H. pylori (especially with atrophic gastritis) impairs absorption, causing deficiency
- iron deficiency — H. pylori competes for iron and induces hepcidin, contributing to anemia of chronic disease
- hygiene hypothesis — H. pylori loss in developed nations correlates with rising asthma, allergies, and autoimmune diseases
¶ Module References
- Module 4
- Module 6